Competition Forces Price Cuts, But Novo Nordisk Is Unstoppable

Novo raises its top- and bottom-line guidance as it prioritizes volume over price.    

 Denmark flag with sunrise
• Source: Bilalulker / Alamy Stock Photo

The US approval of Wegovy (semaglutide) for reducing cardiovascular events in obese patients, which arrived in March, was fantastic news for Novo Nordisk A/S overall, but it does have a downside. Since the approval enables the GLP-1 agonist’s coverage by Medicare, it will also enable the payer to negotiate Wegovy’s price.

This is not an immediate concern, however, and even the fact that the group has already cut Wegovy’s US price...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By 

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By 

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.